Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes

The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve di erent pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year.Marine-based pharmaceuticals have started to impactmodern pharmacology and different anti-cancer drugs derived frommarine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use.

Saved in:
Bibliographic Details
Main Authors: Barreca, Marilia, Spanò, Virginia, Montalbano, Alessandra, Cueto, Mercedes, Díaz Marrero, Ana R., Deniz, Irem, Erdoğan, Ayşegül, Lukić Bilela, Lada, Moulin, Corentin, Taffin-de-Givenchy, Elisabeth, Spriano, Filippo, Perale, Giuseppe, Mehiri, Mohamed, Rotter, Ana, Thomas, Olivier P., Barraja, Paola, Gaudêncio, Susana P., Bertoni, Francesco
Other Authors: European Cooperation in Science and Technology
Format: artículo de revisión biblioteca
Language:English
Published: Multidisciplinary Digital Publishing Institute 2020-12-04
Subjects:Marine natural products, Marine drugs, Anticancer, Drug discovery, Clinical pipeline,
Online Access:http://hdl.handle.net/10261/224408
http://dx.doi.org/10.13039/501100000921
http://dx.doi.org/10.13039/501100004837
http://dx.doi.org/10.13039/501100001871
Tags: Add Tag
No Tags, Be the first to tag this record!
id dig-ipna-es-10261-224408
record_format koha
spelling dig-ipna-es-10261-2244082021-12-28T16:53:08Z Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes Barreca, Marilia Spanò, Virginia Montalbano, Alessandra Cueto, Mercedes Díaz Marrero, Ana R. Deniz, Irem Erdoğan, Ayşegül Lukić Bilela, Lada Moulin, Corentin Taffin-de-Givenchy, Elisabeth Spriano, Filippo Perale, Giuseppe Mehiri, Mohamed Rotter, Ana Thomas, Olivier P. Barraja, Paola Gaudêncio, Susana P. Bertoni, Francesco European Cooperation in Science and Technology Fundação para a Ciência e a Tecnologia (Portugal) Slovenian Research Agency Ministerio de Ciencia e Innovación (España) Cabildo de Tenerife Marine natural products Marine drugs Anticancer Drug discovery Clinical pipeline The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve di erent pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year.Marine-based pharmaceuticals have started to impactmodern pharmacology and different anti-cancer drugs derived frommarine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use. This publication is based upon work from COST Action CA18238 (Ocean4Biotech), supported by COST (European Cooperation in Science and Technology) programme. This work was partially supported by the Applied Molecular Biosciences Unit-UCIBIO (UID/Multi/04378/2019), financed by national funds from FCT/MCTES. Additionally, support was received from the FCT/MCTES through grant IF/00700/2014 (to SPG); the Slovenian Research Agency research core funding P1-0245 (to AR); TÜB˙ITAK grant number 216Z167 (to AE); the Ministerio de Ciencia e Innovación (grant RTA 2015-00010-C03-02) (to MC); the Agustin de Betancourt Programme (Cabildo de Tenerife, TFinnova Programme supported by MEDI and FDCAN funds) (to ARDM); the MetaboCell project of Canceropôle Provence-Alpes-Côte d’Azur and the Provence-Alpes-Côte d’Azur Region (to MM). This project (to OPT, Grant-Aid Agreements No. PBA/MB/16/01 and PDOC/19/02/01) was carried out with the support of the Marine Institute and funded under the Marine Research Programme by the Irish Government. Peer reviewed 2020-12-04T10:55:28Z 2020-12-04T10:55:28Z 2020-12-04 artículo de revisión http://purl.org/coar/resource_type/c_dcae04bc Marine Drugs 18, 619: 1-28 (2020) http://hdl.handle.net/10261/224408 10.3390/md18120619 1660-3397 http://dx.doi.org/10.13039/501100000921 http://dx.doi.org/10.13039/501100004837 http://dx.doi.org/10.13039/501100001871 33291602 en Publisher's version https://doi.org/10.3390/md18120619 Sí open Multidisciplinary Digital Publishing Institute
institution IPNA ES
collection DSpace
country España
countrycode ES
component Bibliográfico
access En linea
databasecode dig-ipna-es
tag biblioteca
region Europa del Sur
libraryname Biblioteca del IPNA España
language English
topic Marine natural products
Marine drugs
Anticancer
Drug discovery
Clinical pipeline
Marine natural products
Marine drugs
Anticancer
Drug discovery
Clinical pipeline
spellingShingle Marine natural products
Marine drugs
Anticancer
Drug discovery
Clinical pipeline
Marine natural products
Marine drugs
Anticancer
Drug discovery
Clinical pipeline
Barreca, Marilia
Spanò, Virginia
Montalbano, Alessandra
Cueto, Mercedes
Díaz Marrero, Ana R.
Deniz, Irem
Erdoğan, Ayşegül
Lukić Bilela, Lada
Moulin, Corentin
Taffin-de-Givenchy, Elisabeth
Spriano, Filippo
Perale, Giuseppe
Mehiri, Mohamed
Rotter, Ana
Thomas, Olivier P.
Barraja, Paola
Gaudêncio, Susana P.
Bertoni, Francesco
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
description The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve di erent pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year.Marine-based pharmaceuticals have started to impactmodern pharmacology and different anti-cancer drugs derived frommarine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use.
author2 European Cooperation in Science and Technology
author_facet European Cooperation in Science and Technology
Barreca, Marilia
Spanò, Virginia
Montalbano, Alessandra
Cueto, Mercedes
Díaz Marrero, Ana R.
Deniz, Irem
Erdoğan, Ayşegül
Lukić Bilela, Lada
Moulin, Corentin
Taffin-de-Givenchy, Elisabeth
Spriano, Filippo
Perale, Giuseppe
Mehiri, Mohamed
Rotter, Ana
Thomas, Olivier P.
Barraja, Paola
Gaudêncio, Susana P.
Bertoni, Francesco
format artículo de revisión
topic_facet Marine natural products
Marine drugs
Anticancer
Drug discovery
Clinical pipeline
author Barreca, Marilia
Spanò, Virginia
Montalbano, Alessandra
Cueto, Mercedes
Díaz Marrero, Ana R.
Deniz, Irem
Erdoğan, Ayşegül
Lukić Bilela, Lada
Moulin, Corentin
Taffin-de-Givenchy, Elisabeth
Spriano, Filippo
Perale, Giuseppe
Mehiri, Mohamed
Rotter, Ana
Thomas, Olivier P.
Barraja, Paola
Gaudêncio, Susana P.
Bertoni, Francesco
author_sort Barreca, Marilia
title Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
title_short Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
title_full Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
title_fullStr Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
title_full_unstemmed Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
title_sort marine anticancer agents: an overview with a particular focus on their chemical classes
publisher Multidisciplinary Digital Publishing Institute
publishDate 2020-12-04
url http://hdl.handle.net/10261/224408
http://dx.doi.org/10.13039/501100000921
http://dx.doi.org/10.13039/501100004837
http://dx.doi.org/10.13039/501100001871
work_keys_str_mv AT barrecamarilia marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT spanovirginia marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT montalbanoalessandra marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT cuetomercedes marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT diazmarreroanar marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT denizirem marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT erdoganaysegul marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT lukicbilelalada marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT moulincorentin marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT taffindegivenchyelisabeth marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT sprianofilippo marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT peralegiuseppe marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT mehirimohamed marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT rotterana marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT thomasolivierp marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT barrajapaola marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT gaudenciosusanap marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
AT bertonifrancesco marineanticanceragentsanoverviewwithaparticularfocusontheirchemicalclasses
_version_ 1777669880688934912